CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Sanofi-Aventis U.S. LLC v. Apotex, Inc.

1:16-cv-01312

Overview

Case Number 1:16-cv-01312
Filing Date 2016-12-27
Status Terminated
Termination Date 2017-05-03
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Sanofi Operating Company

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Apotex Corp. Operating Company

Represented By

2 Attorneys Listed

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Sanofi-Aventis U.S. LLC Operating Company

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Plaintiff

Aventisub LLC Operating Company

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Genzyme Corporation NPE (Individual / Inventor)

Represented By

7 Attorneys Listed

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Brandon J. Kennedy

Email: kennedy@mbhb.com

Ann C. Palma

Email: palma@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Counter Claimant

Apotex, Inc. Operating Company

Represented By

2 Attorneys Listed

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 10 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB 🇺🇸 US
Parallel Proceedings Across Jurisdictions (10 found):
U.S. Courts: 10
U.S. District Court 2017-01-25
1:17-cv-00070

Sanofi-Aventis U.S. LLC v. Emcure Pharmaceuticals Ltd.

U.S. Family Sibling (["US6794410"])
Status: DED
U.S. District Court 2017-01-12
1:17-cv-00040

Sanofi-Aventis U.S. LLC v. Par Pharmaceutical, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-12
1:17-cv-00039

Sanofi-Aventis U.S. LLC v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2017-01-11
1:17-cv-00034

Sanofi-Aventis U.S. LLC v. Zydus Pharmaceuticals (USA) Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-11
1:17-cv-00031

Sanofi-Aventis U.S. LLC v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-10
1:17-cv-00027

Sanofi-Aventis U.S. LLC v. MSN Laboratories Private Limited

Asserted Patent
Status: DED
U.S. District Court 2017-01-10
1:17-cv-00024

Sanofi-Aventis U.S. LLC v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-05
1:17-cv-00019

Sanofi-Aventis U.S. LLC v. Breckenridge Pharmaceutical, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-01-05
1:17-cv-00018

Sanofi-Aventis U.S. LLC v. Teva Pharmaceuticals USA, Inc.

U.S. Family Sibling (["US6794410"])
Status: DED
U.S. District Court 2017-01-03
1:17-cv-00003

Sanofi-Aventis U.S. LLC v. Biocon Limited

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6794410
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Filed: 2002-04-01
Issued: 2004-09-21
Expired (Term Ended) +1639d PTA
Expires: 2026-09-26
US9186346
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Filed: 2014-02-04
Issued: 2015-11-17
Active (7.2 yrs remaining)
Expires: 2034-02-04

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1639 days) / Cellect Scrutiny — Over 1639 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

8

Dispositive

0

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Procedural / Extension Motion 8

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED - re 16 STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to May 1, 2017 filed by Aventisub LLC, Genzyme Corporation, ...
Entry #— • 2017-04-11
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Move, Answer or Otherwise Respond to the Complaint to May 1, 2017 - filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi-Av...
Entry #16 • 2017-04-10 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to April 10, 2017 - filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi-Ave...
Entry #15 • 2017-03-10 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 15 STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to April 10, 2017 filed by Aventisub LLC, Genzyme Corporation, Sa...
Entry #— • 2017-03-10
Procedural / Extension Motion Pending
SO ORDERED - re 13 STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to March 10, 2017 filed by Aventisub LLC, Genzyme Corporation, S...
Entry #— • 2017-02-08
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Answer, Move or Otherwise Respond to Complaint to March 10, 2017 - filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi-Ave...
Entry #13 • 2017-02-07 Document →

Docket Entries

(36 total)
Pleading / Complaint

COMPLAINT filed against Apotex Corp., Apotex, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2054758.) - filed by Sanofi-Aventis U.S. LLC, Aventisub LLC, Sanofi, Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(jcs) (Entered: 12/28/2016)

Entry #1 • 2016-12-27
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 12/28/2016)

Entry #2 • 2016-12-27
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: November 18, 2016. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 5/18/2019. (jcs) (Entered: 12/28/2016)

Entry #3 • 2016-12-27
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 B2. (jcs) (Entered: 12/28/2016)

Entry #4 • 2016-12-27
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Aventisub LLC, Genzyme Corporation, Sanofi-Aventis U.S. LLC filed by Aventisub LLC, Genzyme Corporation, Sanofi, Sanofi-Aventis U.S. LLC. (Bove, Jeffrey) (Entered: 12/28/2016)

Entry #5 • 2016-12-28
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc